(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases...
Stats | |
---|---|
今日成交量 | 6 585.00 |
平均成交量 | 2 534.00 |
市值 | 88.44B |
EPS | €0 ( 2024-04-25 ) |
下一个收益日期 | ( €0 ) 2024-07-26 |
Last Dividend | €0.570 ( 2023-07-06 ) |
Next Dividend | €0 ( N/A ) |
P/E | 12.10 |
ATR14 | €0.0880 (0.21%) |
音量 相关性
Bristol-Myers Squibb Co 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Bristol-Myers Squibb Co 相关性 - 货币/商品
Bristol-Myers Squibb Co 财务报表
Annual | 2023 |
营收: | €45.01B |
毛利润: | €34.31B (76.24 %) |
EPS: | €3.88 |
FY | 2023 |
营收: | €45.01B |
毛利润: | €34.31B (76.24 %) |
EPS: | €3.88 |
FY | 2022 |
营收: | €46.16B |
毛利润: | €36.02B (78.04 %) |
EPS: | €2.97 |
FY | 2021 |
营收: | €46.39B |
毛利润: | €36.45B (78.57 %) |
EPS: | €3.15 |
Financial Reports:
No articles found.
Bristol-Myers Squibb Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0.540 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.215 | 1999-06-30 |
Last Dividend | €0.570 | 2023-07-06 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 97 | -- |
Total Paid Out | €33.94 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.93 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.68 | |
Div. Directional Score | 8.19 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
HAG.DE | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% | |
RHK.DE | Ex Dividend Junior | 2023-06-09 | Sporadic | 0 | 0.00% | |
BSL.DE | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
IXX.DE | Ex Dividend Knight | 2023-05-26 | Annually | 0 | 0.00% | |
SZG.DE | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
DBK.DE | Ex Dividend Junior | 2023-05-18 | Sporadic | 0 | 0.00% | |
MBG.DE | Ex Dividend Knight | 2023-05-04 | Annually | 0 | 0.00% | |
47T.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% | |
VOS.DE | Ex Dividend Junior | 2023-05-25 | Sporadic | 0 | 0.00% | |
EUZ.DE | Ex Dividend Knight | 2023-06-08 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.178 | 1.500 | 6.43 | 9.65 | [0 - 0.5] |
returnOnAssetsTTM | 0.0843 | 1.200 | 7.19 | 8.63 | [0 - 0.3] |
returnOnEquityTTM | 0.263 | 1.500 | 8.19 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.591 | -1.000 | 4.09 | -4.09 | [0 - 1] |
currentRatioTTM | 1.427 | 0.800 | 7.86 | 6.29 | [1 - 3] |
quickRatioTTM | 1.237 | 0.800 | 7.43 | 5.94 | [0.8 - 2.5] |
cashRatioTTM | 0.515 | 1.500 | 8.25 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.436 | -1.500 | 2.74 | -4.11 | [0 - 0.6] |
interestCoverageTTM | 8.08 | 1.000 | 8.12 | 8.12 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.82 | 2.00 | 7.73 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.23 | 2.00 | 6.89 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.409 | -1.500 | 4.36 | -6.55 | [0 - 2.5] |
grossProfitMarginTTM | 0.762 | 1.000 | 0.627 | 0.627 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.209 | 1.000 | 7.82 | 7.82 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.334 | 1.000 | 9.25 | 9.25 | [0.2 - 2] |
assetTurnoverTTM | 0.473 | 0.800 | -0.180 | -0.144 | [0.5 - 2] |
Total Score | 10.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.47 | 1.000 | 8.94 | 0 | [1 - 100] |
returnOnEquityTTM | 0.263 | 2.50 | 8.84 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.23 | 2.00 | 7.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.258 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.82 | 2.00 | 7.73 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.591 | 1.500 | 4.09 | -4.09 | [0 - 1] |
pegRatioTTM | 0.194 | 1.500 | -2.04 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.308 | 1.000 | 4.80 | 0 | [0.1 - 0.5] |
Total Score | 5.68 |
Bristol-Myers Squibb Co
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。